Simeprevir Has High SVR Rate in Hep C Trial
Share
Follow Us
The Editors at Hepatitis Central
May 28, 2013
In a Phase III Hepatitis C trial of triple therapy with pegylated interferon and ribavirin, simeprevir proves itself by leading to sustained virologic response in nearly 80 percent of patients.
Sustained Virologic Response with Simeprevir for Hepatitis C
May 21, 2013
Janssen R&D Ireland announced primary efficacy and safety results from its global Phase 3 PROMISE study. Simeprevir (TMC435) is an investigational NS3/4A protease inhibitor for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis.
Continue reading this entire article:
http://www.empr.com/sustained-virologic-response-with-simeprevir-for-hepatitis-c/article/294292/#
